Amotz Shemi

Dr Amotz Shemi is an Israeli scientist based in New York. He is the CEO of Silenseed Ltd, a biotech company developing non-chemotherapy treatment for solid tumors based on the company's proprietary Small interfering RNA (siRNA) delivery platform.
Early life
Shemi trained as a theoretical astrophysicist, receiving his PhD from Tel Aviv University with a thesis dealing with cosmic fireballs and gamma-ray bursts published in 1993. Upon completing his PhD, Shemi worked on the TAUVEX project as Project Scientist.
Academic work
Most of his works are published in astrophysics including "Are Unidentified EUV Sources the Closest Neutron Stars?", "COSMIC RAYS FROM ACCRETING ISOLATED NEUTRON STARS", and "Gamma Ray Bursts from Interaction of Relativistic Flows with Radiation Fields". He currently has two patents. One for the system and method for the fabrication of an electro-optical module 01-15-2009 and on the methods and process of tapering waveguides and of forming optimized waveguide structures .
Business interests
As of June 2010, Shemi serves as the CEO of Silenseed Ltd, a biotech company developing non-chemotherapy treatment for solid tumors based on the company's proprietary siRNA delivery platform.
From 2005 to 2008 Dr. Shemi served as the Senior V.P. Technologies in Medinol, a company specialising in minimally-invasive cardiovascular stent technology.
Prior to Medinol, Shemi served as the CEO of ColorChip, and CEO of WANWay Technologies.

Main Menu

See Also

Main Menu